Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellström-Lindahl E, Andreasen N, Minthon L, Nordberg A. Darreh-Shori T, et al. Among authors: andreasen n. J Neural Transm (Vienna). 2006 Nov;113(11):1791-801. doi: 10.1007/s00702-006-0526-2. Epub 2006 Aug 1. J Neural Transm (Vienna). 2006. PMID: 16868793 Clinical Trial.
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Långström B, Nordberg A. Darreh-Shori T, et al. Among authors: andreasen n. Neurobiol Aging. 2011 Dec;32(12):2320.e15-32. doi: 10.1016/j.neurobiolaging.2010.04.028. Epub 2010 Jun 9. Neurobiol Aging. 2011. PMID: 20538374
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
Karami A, Eyjolfsdottir H, Vijayaraghavan S, Lind G, Almqvist P, Kadir A, Linderoth B, Andreasen N, Blennow K, Wall A, Westman E, Ferreira D, Kristoffersen Wiberg M, Wahlund LO, Seiger Å, Nordberg A, Wahlberg L, Darreh-Shori T, Eriksdotter M. Karami A, et al. Among authors: andreasen n. Alzheimers Dement. 2015 Nov;11(11):1316-28. doi: 10.1016/j.jalz.2014.11.008. Epub 2015 Feb 9. Alzheimers Dement. 2015. PMID: 25676388
Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
Eyjolfsdottir H, Eriksdotter M, Linderoth B, Lind G, Juliusson B, Kusk P, Almkvist O, Andreasen N, Blennow K, Ferreira D, Westman E, Nennesmo I, Karami A, Darreh-Shori T, Kadir A, Nordberg A, Sundström E, Wahlund LO, Wall A, Wiberg M, Winblad B, Seiger Å, Wahlberg L, Almqvist P. Eyjolfsdottir H, et al. Among authors: andreasen n. Alzheimers Res Ther. 2016 Jul 7;8(1):30. doi: 10.1186/s13195-016-0195-9. Alzheimers Res Ther. 2016. PMID: 27389402 Free PMC article. Clinical Trial.
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Sjögren M, Hesse C, Basun H, Köl G, Thostrup H, Kilander L, Marcusson J, Edman A, Wallin A, Karlsson I, Troell M, Wachtmaister G, Ekdahl A, Olofsson H, Sandström A, Andreasen N, Minthon L, Blennow K. Sjögren M, et al. Among authors: andreasen n. J Neural Transm (Vienna). 2001;108(4):451-8. doi: 10.1007/s007020170066. J Neural Transm (Vienna). 2001. PMID: 11475012 Clinical Trial.
632 results